BDM-2

BDM-2 is an IN-LEDGF allosteric inhibitor (INLAI) of HIV-1 integrase (IN refers to integrase) (IC50=47 nM) with potent anti-Retroviral (ARV) activity. BDM-2 shows IN multimerization activation effect with an AC50 value of 20 nM. BDM-2 blocks the interaction between the catalytic core domain of IN (IN-CCD) and the Integrase binding domain of LEDGF/p75 (IBD), with an IC50 value of 0.15 μM. BDM-2 exhibits highly selective and favorable cytotoxicity[1].

Product Specifications

CAS Number

[1643876-33-8]

UNSPSC

12352005

Target

HIV; HIV Integrase

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/bdm-2.html

Concentration

10mM

Purity

99.09

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(C)(C)O[C@@H](C1=C(C2=CC=C(OCCC3)C3=C2)C(C4CC4)=CC=C1C)C(O)=O

Molecular Formula

C25H30O4

Molecular Weight

394.50

References & Citations

[1]Le Rouzic E, et al. Biological and structural analysis of new potent Integrase-LEDGF allosteric HIV-1 inhibitors. bioRxiv, 2023: 2023.01. 28.523533.